Nebula Research & Development LLC Has $775,000 Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Nebula Research & Development LLC reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 47.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,332 shares of the company's stock after selling 2,146 shares during the quarter. Nebula Research & Development LLC's holdings in Medpace were worth $775,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after purchasing an additional 25,704 shares during the last quarter. Invesco Ltd. raised its stake in shares of Medpace by 91.8% in the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after acquiring an additional 519,186 shares during the last quarter. Wasatch Advisors LP lifted its position in shares of Medpace by 3.1% during the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after purchasing an additional 28,161 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Medpace by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after purchasing an additional 28,076 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of Medpace by 15.0% in the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock valued at $191,379,000 after purchasing an additional 75,275 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MEDP. Leerink Partners started coverage on Medpace in a research report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Robert W. Baird decreased their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $349.30.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is owned by insiders.

Medpace Price Performance

Shares of Medpace stock traded up $2.86 on Friday, hitting $305.11. The company had a trading volume of 313,502 shares, compared to its average volume of 343,385. The stock has a 50-day moving average of $309.90 and a 200-day moving average of $330.13. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The firm has a market capitalization of $8.77 billion, a P/E ratio of 24.16, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the business earned $3.20 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.